These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38856768)

  • 1. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for new-onset gastric cancer and gastric diseases in patients with type 2 diabetes mellitus: a population-based cohort study.
    Chou OHI; Chauhan VK; Chung CTS; Lu L; Lee TTL; Ng ZMW; Wang KKW; Lee S; Liu H; Pang RTK; Kaewdech A; Cheung BMY; Tse G; Zhou J
    Gastric Cancer; 2024 Sep; 27(5):947-970. PubMed ID: 38856768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong.
    Lee S; Zhou J; Leung KSK; Wai AKC; Jeevaratnam K; King E; Liu T; Wong WT; Chang C; Wong ICK; Cheung BMY; Tse G; Zhang Q
    Cardiovasc Drugs Ther; 2023 Jun; 37(3):561-569. PubMed ID: 35142921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New-onset syncope in diabetic patients treated with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors: a Chinese population-based cohort study.
    Gao X; Zhang N; Lu L; Gao T; Chou OHI; Wong WT; Chang C; Wai AKC; Lip GYH; Zhang Q; Tse G; Liu T; Zhou J
    Eur Heart J Cardiovasc Pharmacother; 2024 Feb; 10(2):103-117. PubMed ID: 37962962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors on new-onset depression: a propensity score-matched study in Hong Kong.
    Mui JV; Li L; Chou OHI; Azfar N; Lee A; Hui J; Lee S; Tse G; Zhou J
    Acta Diabetol; 2023 Jul; 60(7):917-927. PubMed ID: 37000300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes.
    Zhou J; Liu X; Chou OH; Li L; Lee S; Wong WT; Zhang Q; Chang C; Liu T; Tse G; Jing F; Cheung BMY
    Rheumatology (Oxford); 2023 Apr; 62(4):1501-1510. PubMed ID: 36066415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of lower limb amputation in diabetic patients using SGLT2 inhibitors
    Lu Y; Guo C
    Ther Adv Drug Saf; 2023; 14():20420986231178126. PubMed ID: 37332886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incident heart failure and myocardial infarction in sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitor users.
    Zhou J; Lee S; Leung KSK; Wai AKC; Liu T; Liu Y; Chang D; Wong WT; Wong ICK; Cheung BMY; Zhang Q; Tse G
    ESC Heart Fail; 2022 Apr; 9(2):1388-1399. PubMed ID: 35132823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study.
    Chan YH; Chao TF; Chen SW; Lee HF; Li PR; Chen WM; Yeh YH; Kuo CT; See LC; Lip GYH
    Cardiovasc Diabetol; 2022 Jun; 21(1):118. PubMed ID: 35765074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lower Risks of New-Onset Hepatocellular Carcinoma in Patients With Type 2 Diabetes Mellitus Treated With SGLT2 Inhibitors Versus DPP4 Inhibitors.
    Chou OHI; Ning J; Chan RNC; Chung CT; Huang H; Ng K; Dee EC; Lee S; Kaewdech A; Chow AKM; Man NK; Liu T; Jing F; Cheung BMY; Tse G; Zhou J
    J Natl Compr Canc Netw; 2024 Jun; 22(2D):. PubMed ID: 38862004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis.
    Mui JV; Zhou J; Lee S; Leung KSK; Lee TTL; Chou OHI; Tsang SL; Wai AKC; Liu T; Wong WT; Chang C; Tse G; Zhang Q
    Front Cardiovasc Med; 2021; 8():747620. PubMed ID: 34746262
    [No Abstract]   [Full Text] [Related]  

  • 11. Sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new-onset overall cancer in Type 2 diabetes mellitus: A population-based study.
    Chung CT; Lakhani I; Chou OHI; Lee TTL; Dee EC; Ng K; Wong WT; Liu T; Lee S; Zhang Q; Cheung BMY; Tse G; Zhou J
    Cancer Med; 2023 Jun; 12(11):12299-12315. PubMed ID: 37148547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary Occurrence of Cardiovascular Events After Adding Sodium-Glucose Cotransporter-2 Inhibitors or Glucagon-like Peptide-1 Receptor Agonists Compared With Dipeptidyl Peptidase-4 Inhibitors: A Cohort Study in Veterans With Diabetes.
    Richardson TL; Halvorson AE; Hackstadt AJ; Hung AM; Greevy R; Grijalva CG; Elasy TA; Roumie CL
    Ann Intern Med; 2023 Jun; 176(6):751-760. PubMed ID: 37155984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors.
    Ling AW; Chan CC; Chen SW; Kao YW; Huang CY; Chan YH; Chu PH
    Cardiovasc Diabetol; 2020 Nov; 19(1):188. PubMed ID: 33158436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Sodium-Glucose Cotransporter 2 Inhibitor vs Dipeptidyl Peptidase-4 Inhibitor Use With Risk of Incident Obstructive Airway Disease and Exacerbation Events Among Patients With Type 2 Diabetes in Hong Kong.
    Au PCM; Tan KCB; Lam DCL; Cheung BMY; Wong ICK; Kwok WC; Sing CW; Cheung CL
    JAMA Netw Open; 2023 Jan; 6(1):e2251177. PubMed ID: 36648944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of SGLT2 inhibitors, DPP-4 inhibitors, and GLP-1 receptor agonists in US veterans with and without chronic kidney disease: a population-based study.
    Narasaki Y; Kovesdy CP; You AS; Sumida K; Mallisetty Y; Surbhi S; Thomas F; Amin AN; Streja E; Kalantar-Zadeh K; Rhee CM
    Lancet Reg Health Am; 2024 Aug; 36():100814. PubMed ID: 38993538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fracture risks associated with sodium-glucose cotransporter-2 inhibitors in type 2 diabetes patients across eGFR and albuminuria categories: A population-based study in Hong Kong.
    Lui DTW; Wu T; Tang EHM; Au ICH; Lee CH; Woo YC; Tan KCB; Wong CKH
    Diabetes Res Clin Pract; 2023 Mar; 197():110576. PubMed ID: 36780955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes.
    Paik JM; Tesfaye H; Curhan GC; Zakoul H; Wexler DJ; Patorno E
    JAMA Intern Med; 2024 Mar; 184(3):265-274. PubMed ID: 38285598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-Line Pharmaceutical Treatments for Patients with Type 2 Diabetes.
    Vashisht R; Patel A; Dahm L; Han C; Medders KE; Mowers R; Byington CL; Koliwad SK; Butte AJ
    JAMA Netw Open; 2023 Oct; 6(10):e2336613. PubMed ID: 37782497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.
    Kanie T; Mizuno A; Takaoka Y; Suzuki T; Yoneoka D; Nishikawa Y; Tam WWS; Morze J; Rynkiewicz A; Xin Y; Wu O; Providencia R; Kwong JS
    Cochrane Database Syst Rev; 2021 Oct; 10(10):CD013650. PubMed ID: 34693515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucose-Lowering Agents and the Risk of Hypoglycemia: a Real-world Study.
    Lyu B; Hwang YJ; Selvin E; Jameson BC; Chang AR; Grams ME; Shin JI
    J Gen Intern Med; 2023 Jan; 38(1):107-114. PubMed ID: 35831767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.